KNSANasdaqPharmaceutical PreparationsUS GAAP · USD

Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical need, with emphasis on cardiovascular and inflammatory indications. Its only marketed product is ARCALYST, a biologic sold in the United States for recurrent pericarditis and certain rare autoinflammatory diseases, while its pipeline includes additional IL-1-related and immunology assets.

Kysy yhtiöstä
Liikevaihto678milj. USD
+60,1 %v/v
Liikevoitto (EBIT)77,2milj. USD
+269,3 %v/v
EBIT-marginaali11,4%
+22,2 %-yks.v/v
Nettotulos59,0milj. USD
+236,6 %v/v
Vapaa kassavirta136milj. USD
+436,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−2000200400600800milj. USD2020: EBIT −157 milj. USD20202021: 39 milj. USD2021: EBIT −157 milj. USD20212022: 220 milj. USD2022: EBIT 9,8 milj. USD20222023: 270 milj. USD2023: EBIT −25 milj. USD20232024: 423 milj. USD2024: EBIT −46 milj. USD20242025: 678 milj. USD2025: EBIT 77 milj. USD202567877
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Kiniksa Pharmaceuticals International, plc

Liiketoiminta

Osuus liikevaihdosta
Commercial biologic product95 %

ARCALYST, the company's marketed IL-1 trap therapy sold in the U.S. through specialty pharmacies.

Approved rare disease indications5 %

Approved uses of ARCALYST in recurrent pericarditis, CAPS, and DIRA that drive current sales.

Clinical-stage pipeline0 %

KPL-387 and related programs being developed for recurrent pericarditis and other inflammatory diseases.

Preclinical assets0 %

Earlier-stage immunology and cardiovascular programs such as KPL-1161 and other assets.

Tuotteet

Raportoitu · osuus liikevaihdosta
98,5%FY2024100 %
  • Products98,5 %
  • Collaboration1,5 %

Lähde: 10-K FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Kiniksa sells primarily to a select network of third-party specialty pharmacies and logistics partners, which then dispense ARCALYST to patients by mail. Demand is driven by physicians treating rare inflammatory and cardiovascular diseases, while reimbursement depends on payors and insurers that determine access and coverage. Because the company has only one commercial product, customer concentration and channel execution are central to the business model.

Specialty pharmacies

They buy ARCALYST for distribution, patient support, and prescription fulfillment, making them the core commercial channel.

Physicians and treatment centers

Cardiologists, rheumatologists, and specialists prescribe ARCALYST for approved rare-disease indications.

Patients with recurrent pericarditis

Patients with painful inflammatory cardiovascular disease who need ongoing biologic treatment.

Rare disease patients with CAPS or DIRA

Small patient groups using ARCALYST for approved orphan indications.

Payors and insurers

They do not buy the drug directly but determine reimbursement, coverage, and patient access.

Strategia

Kiniksa's strategy is to expand ARCALYST commercialization in recurrent pericarditis while maintaining access and reimbursement support through its specialty pharmacy network. At the same time, it is advancing follow-on IL-1 and immunology programs to reduce dependence on a single product and broaden its long-term pipeline. Capital discipline remains important because the company expects continued spending on manufacturing, sales infrastructure, and clinical development.

Grow ARCALYST in recurrent pericarditisLyhyt aikaväli

It is the company's only commercial product and main revenue driver.

Maintain access and reimbursementLyhyt aikaväli

Rare-disease demand depends on coverage, pricing, and specialty pharmacy execution.

Advance pipeline diversificationKeskipitkä aikaväli

A broader pipeline reduces single-product dependence and supports future growth.

Maantiede

The company is headquartered in the United States, with executive offices in Massachusetts and a registered office in London following its 2024 redomiciliation to the UK. Commercial revenue is currently generated almost entirely in the United States because ARCALYST is approved for sale only there. The company also maintains subsidiaries and tax presence in the UK, Switzerland, Germany, and France to support development, IP ownership, and international structuring.

Riskit

The company is highly dependent on ARCALYST, so any slowdown in uptake, reimbursement pressure, or competitive entry could materially affect revenue. Its business also relies on third parties for manufacturing, logistics, and specialty pharmacy distribution, which creates supply and execution risk in a regulated biologics market. Clinical development, regulatory approval, and the ability to fund operations remain important risks because the pipeline is still early and the company may need additional capital.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Dependence on ARCALYST commercialization1Third-party manufacturing and supply chain reliance2Reimbursement and payor pressure3Competition in IL-1 and inflammatory diseases4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Dependence on ARCALYST commercializationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company has one marketed product, so any demand or access disruption can materially affect revenue.

    Kohdistuu: U.S. rare-disease biologic sales

  2. Third-party manufacturing and supply chain relianceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Commercial and clinical supply are outsourced, and biologic inputs can be scarce or single-sourced.

    Kohdistuu: Product availability and launch execution

  3. Reimbursement and payor pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Coverage and pricing decisions directly affect patient access and net revenue realization.

    Kohdistuu: Specialty pharmacy channel and U.S. payors

  4. Competition in IL-1 and inflammatory diseasesVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Other drugs may offer more convenient dosing or alternative mechanisms in the same indications.

    KohdistuuRecurrent pericarditisCAPSDIRA
Kysy Clarifolta: Kiniksa Pharmaceuticals International, plc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition and variable consideration

Net sales depend on estimates for discounts, rebates, returns, and copay assistance.

Vaikutus: Can move quarterly revenue and gross-to-net margins.

Accrued research and development expenses

Clinical and preclinical programs require estimates for vendor services and trial costs.

Vaikutus: Affects operating expense timing and comparability.

Deferred tax assets and uncertain tax positions

The company has tax attributes and multinational structure that require judgment on realizability and positions.

Vaikutus: Can affect tax expense and balance sheet valuation allowances.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Oruka Therapeutics, Inc.

ORKA · Pharmaceutical Preparations

Aclaris Therapeutics, Inc.

ACRS · Pharmaceutical Preparations

Aurinia Pharmaceuticals Inc.

AUPH · Pharmaceutical Preparations

KalVista Pharmaceuticals, Inc.

Pharmaceutical Preparations

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

Inhibikase Therapeutics, Inc.

IKT · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026

Kiniksa Pharmaceuticals International, plc (KNSA) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo